These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Author: Loriot MA, Beaune P.
    Journal: Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618.
    Abstract:
    INTRODUCTION: Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors. EXEGESIS: VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for the carboxylation step of clotting factors. VKORC1 is the target enzyme of inhibition by oral anticoagulants or anti-vitamin K (warfarin, acenocoumarol). CONCLUSION: We show here the clinical consequences of genetic variations of VKORC1 during VKA therapy.
    [Abstract] [Full Text] [Related] [New Search]